Literature DB >> 326202

[Influence of autologous serum on leucocyte-migration-inhibition-test in melanomalignoma (author's transl)].

J Fritz, K Grond.   

Abstract

Influence of autologous serum on cellular immunological reactivity to melanomalignoma (MM)-associated antigens was examined on 20 patients have MM at different clinical stages, using the Leucocyte-Migration-Inhibition-Test (MIT). These 20 patients were referring to this till now not investigated. When heterologous serum (horse serum) was supplemented, an inhibition of cell-migration could be established in 15/20 cases, whereas a cell-migration inhibition in 14/20 cases was absent if autologous serum was added to culture medium. No correlation could be found between our test results and the clinical stage of the disease. Our results suggests urgently that blocking factors are present in serum of MM-patients. There is reason to believe that this factors will be active in lymphocyte level.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326202     DOI: 10.1007/bf00561616

Source DB:  PubMed          Journal:  Arch Dermatol Res            Impact factor:   3.017


  33 in total

1.  Tumor-specific antigen solubilized by hypertonic potassium chloride.

Authors:  M S Meltzer; E J Leonard; H J Rapp; T Borsos
Journal:  J Natl Cancer Inst       Date:  1971-09       Impact factor: 13.506

2.  Possible explanation for loss of detectable antibody in patients with disseminated malignant melanoma.

Authors:  M G Lewis; T M Phillips; K B Cook; J Blake
Journal:  Nature       Date:  1971-07-02       Impact factor: 49.962

3.  Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas.

Authors:  I Hellström; K E Hellström
Journal:  Int J Cancer       Date:  1970-03-15       Impact factor: 7.396

4.  In vitro cellular responses to autologous tumor extract detected by inhibition of macrophage migration.

Authors:  T Akiyoshi; A Hata; H Tsuji
Journal:  Gan       Date:  1975-04

Review 5.  Microcytotoxicity and serum blocking factors in malignant melanoma and halo nevus.

Authors:  H H Roenigk; S D Deodhar; J A Krebs; B Barna
Journal:  Arch Dermatol       Date:  1975-06

6.  Cellular and humoral immunity against human malignant melanoma.

Authors:  G Fossati; M I Colnaghi; G D Porta; N Cascinelli; U Veronesi
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

7.  Soluble HL-A antigens in serum. I. Isolation and purification.

Authors:  S K Oh; M A Pellegrino; S Ferrone; E D Sevier; R A Reisfeld
Journal:  Eur J Immunol       Date:  1975-03       Impact factor: 5.532

8.  Humoral and cellular immune reactions 'in vitro' against allogeneic and autologous human melanoma cells.

Authors:  H H Peter; J R Kalden; P Seeland; V Diehl; G Eckert
Journal:  Clin Exp Immunol       Date:  1975-05       Impact factor: 4.330

9.  Cell-mediated immune reactions to tumor antigens with particular emphasis on immunity to human neoplasms.

Authors:  I Hellström; K E Hellström
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

10.  Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen.

Authors:  G A Currie; C Basham
Journal:  Br J Cancer       Date:  1972-12       Impact factor: 7.640

View more
  2 in total

1.  Human malignant melanoma antigenic properties of phenol water extracts.

Authors:  L Suter; H Tilkorn; P M Kövary
Journal:  Arch Dermatol Res       Date:  1979-02-23       Impact factor: 3.017

2.  Human intracranial tumors: effect of autologous serum addition on leucocyte migration inhibition.

Authors:  D K Böker
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.